These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 21990067)
1. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067 [TBL] [Abstract][Full Text] [Related]
2. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522 [TBL] [Abstract][Full Text] [Related]
3. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. van den Berg CB; Dasgupta S; Ewing-Graham PC; Bart J; Bulten J; Gaarenstroom KN; de Hullu JA; Mom CH; Mourits MJE; Steenbeek MP; van Marion R; van Beekhuizen HJ Gynecol Oncol; 2024 Aug; 187():113-119. PubMed ID: 38759517 [TBL] [Abstract][Full Text] [Related]
4. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Ardighieri L; Mori L; Conzadori S; Bugatti M; Falchetti M; Donzelli CM; Ravaggi A; Odicino FE; Facchetti F Virchows Arch; 2016 Jul; 469(1):61-9. PubMed ID: 27059324 [TBL] [Abstract][Full Text] [Related]
5. The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Soong TR; Howitt BE; Horowitz N; Nucci MR; Crum CP Gynecol Oncol; 2019 Feb; 152(2):426-433. PubMed ID: 30503267 [TBL] [Abstract][Full Text] [Related]
6. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554 [TBL] [Abstract][Full Text] [Related]
7. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Kuhn E; Kurman RJ; Soslow RA; Han G; Sehdev AS; Morin PJ; Wang TL; Shih IeM Am J Surg Pathol; 2012 Dec; 36(12):1826-34. PubMed ID: 22892598 [TBL] [Abstract][Full Text] [Related]
8. Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. Meserve EE; Strickland KC; Miron A; Soong TR; Campbell F; Howitt BE; Crum CP Int J Gynecol Pathol; 2019 Sep; 38(5):443-448. PubMed ID: 29901519 [TBL] [Abstract][Full Text] [Related]
9. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Kuhn E; Meeker A; Wang TL; Sehdev AS; Kurman RJ; Shih IeM Am J Surg Pathol; 2010 Jun; 34(6):829-36. PubMed ID: 20431479 [TBL] [Abstract][Full Text] [Related]
11. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760 [TBL] [Abstract][Full Text] [Related]
12. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
13. Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. Asaka S; Davis C; Lin SF; Wang TL; Heaphy CM; Shih IM Am J Surg Pathol; 2019 Aug; 43(8):1083-1091. PubMed ID: 31107721 [TBL] [Abstract][Full Text] [Related]
15. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555 [TBL] [Abstract][Full Text] [Related]
16. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711 [TBL] [Abstract][Full Text] [Related]
17. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions. Chien YW; Wang Y; Huang P; Lawson BC; Kolin DL; Chui MH; Vang R; Numan TA; Soong TR; Wang BG; Smith SA; Chen CL; Stone R; Douville C; Wang TL; Shih IM Am J Surg Pathol; 2024 Apr; 48(4):475-486. PubMed ID: 38298022 [TBL] [Abstract][Full Text] [Related]
18. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. Kim HN; Woo HY; DO SI; Kim HS In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396 [TBL] [Abstract][Full Text] [Related]
19. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]